scholarly journals Intimal pericytes as the second line of immune defence in atherosclerosis

2015 ◽  
Vol 7 (10) ◽  
pp. 583 ◽  
Author(s):  
Ekaterina A Ivanova
Keyword(s):  
2006 ◽  
Vol 5 (12) ◽  
pp. 21
Author(s):  
MELINDA TANZOLA
Keyword(s):  

2018 ◽  
Vol 23 (3) ◽  
pp. 233-249 ◽  
Author(s):  
Eric Bonetto ◽  
Fabien Girandola ◽  
Grégory Lo Monaco

Abstract. This contribution consists of a critical review of the literature about the articulation of two traditionally separated theoretical fields: social representations and commitment. Besides consulting various works and communications, a bibliographic search was carried out (between February and December, 2016) on various databases using the keywords “commitment” and “social representation,” in the singular and in the plural, in French and in English. Articles published in English or in French, that explicitly made reference to both terms, were included. The relations between commitment and social representations are approached according to two approaches or complementary lines. The first line follows the role of commitment in the representational dynamics: how can commitment transform the representations? This articulation gathers most of the work on the topic. The second line envisages the social representations as determinants of commitment procedures: how can these representations influence the effects of commitment procedures? This literature review will identify unexploited tracks, as well as research perspectives for both areas of research.


2010 ◽  
Vol 40 (2) ◽  
pp. 36
Author(s):  
DIANA MAHONEY
Keyword(s):  

2013 ◽  
Vol 51 (01) ◽  
Author(s):  
A Herber ◽  
K Deterding ◽  
C Jochum ◽  
B Kronenberger ◽  
HH Feucht ◽  
...  
Keyword(s):  

2010 ◽  
Vol 01 (03) ◽  
pp. 117-117
Author(s):  
Alexander Kretzschmar
Keyword(s):  

Postmenopausale Patientinnen mit einem fortgeschrittenen, Hormonrezeptor-positiven Mammakarzinom profitieren in der Second-Line-Therapie von einer Dosiseskalation auf Fulvestrant 500 mg (Faslodex®) mit einer um 20% längeren Zeit bis zur Progression. Die auf dem EBCC7-Kongress vorgestellten Daten sind umso höher einzustufen als die Verträglichkeit gegenüber Fulvestrant 250 mg unverändert blieb. Für Prof. Miguel Martin, Madrid/Spanien, hat die Zulassung von Fulvestrant 500 mg „ein neues Fenster in der Therapie hormonsensitiver postmenopausaler Frauen aufgemacht“.


Sign in / Sign up

Export Citation Format

Share Document